PeptideStack
5.2kquestions
20kanswers
220users

How do I read an impurity table on an orforglipron certificate against the 95.2% headline?

Asked 14 Feb 2026Modified 3 months agoViewed 3.3k times
16

What I am working with: orforglipron · 95.2%.

I have worked this out and I would like someone to find the error, because I suspect there is one.

My working so far, for the record, is below, and I am fairly sure the error is in the unit conversion rather than the algebra.

How many significant figures are actually justified here?

purity
purity

Purity as chromatographic area per cent - the fraction of detected material that is your target peak. It says nothing about how much material is…

833 questions
coa
coa

Certificates of analysis: what fields a useful one carries, how to tell a real analytical report from a marketing document, batch and lot…

771 questions
hplc
hplc

Reverse-phase high-performance liquid chromatography, the workhorse purity method. Column chemistry, mobile-phase choice, gradient slope,…

503 questions
orforglipron
orforglipron

A non-peptide, orally bioavailable small-molecule GLP-1 receptor agonist studied in the ATTAIN programme. It is not a peptide, which changes…

219 questions
shareeditfollowflag
MF
askedmeniscus_film32k2714 Feb 2026

2 Answers

Accepted answer first, then by votes
86

Accepted answer

Sum the table and see whether it reaches 4.8 per cent. A 95.2 per cent headline leaves 4.8 per cent of the detected area unaccounted for, and a related-substances table exists to say what that 4.8 per cent is. If the listed peaks add to 2.88 per cent, the missing 1.92 is unassigned area — real signal the laboratory saw and did not name — and that is a finding, not an omission. Check three things in order: does the table report each impurity as area per cent on the same basis as the headline; is there a reporting threshold below which peaks were discarded; and does the largest single impurity have a limit against it. A table whose entries do not close on 4.8 per cent is not wrong, but it is incomplete in a way the headline conceals.

In practice, gradient slope is the most powerful parameter and almost nobody mentions it, which is why two reports on the same material disagree by a point.

Sample solvent strength affects peak shape — if you inject in strong solvent on a gradient starting in weak solvent, the solvent peak can distort your main peak or create a false shoulder.

It helps to be literal here: gradient slope controls resolution, and gentler slopes resolve co-eluting impurities into separate peaks — so the better method reports the worse purity number.

Published side-by-side method comparisons show that a two-point difference in purity on the same vial is easily explained by method choice alone.

Compare purity within a single laboratory on the same method, never across laboratories.

shareimprove this answerflag
DL
answered · acceptedDr_Otto_Lindqvist72k5818 Apr 2026
Sponsored

Sigma-Aldrich - Certified Reference Materials

Analytical standards and reagents with traceable certificates. Every quantitative result you read inherits the accuracy of the standard behind it.

Shop standards
33

Area percentage is not mass percentage, and conflating the two is the most common misreading of a purity figure.

Mass on column affects detector linearity and peak overlap — overloading broadens peaks and hides neighbours, while underloading improves resolution but loses sensitivity.

To be exact about it, mobile phase additive choice affects ionisation and peak shape — TFA gives sharp peaks but suppresses mass spectrometry signal, formic acid gives worse peaks but preserves signal.

If you are ranking vendors, specify a method and have all samples tested at the same place.

edited 8 May 2026 by plate_count_9k — tightened the wording; no substantive change

shareimprove this answerflag
P9
answeredplate_count_9k78k24829 Apr 2026
The impurity table is the part I now read first, and this explains why. – jonas_ekstrom 9 months ago
add a comment

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.